Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 15.48 SEK Market Closed
Market Cap: 537.3m SEK

Relative Value

The Relative Value of one ORX stock under the Base Case scenario is 37.73 SEK. Compared to the current market price of 15.48 SEK, Orexo AB is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORX Relative Value
Base Case
37.73 SEK
Undervaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
72
Median 3Y
0.9
Median 5Y
1.1
Industry
2.4
Forward
0.9
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.7
Industry
21
Forward
-5.1
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4
Industry
16.2
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.3
Industry
24
vs History
vs Industry
7
Median 3Y
2.9
Median 5Y
2.8
Industry
2
vs History
47
vs Industry
61
Median 3Y
1.3
Median 5Y
1.5
Industry
2.6
Forward
1.5
vs History
47
vs Industry
74
Median 3Y
1.6
Median 5Y
1.7
Industry
5.1
vs History
20
vs Industry
25
Median 3Y
-5.3
Median 5Y
-5
Industry
12.6
Forward
77.5
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
16
Forward
-14.5
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-5.2
Industry
14.4
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.6
Industry
17.6
vs History
12
vs Industry
34
Median 3Y
1.2
Median 5Y
1.4
Industry
1.8

Multiples Across Competitors

ORX Competitors Multiples
Orexo AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Orexo AB
STO:ORX
534.1m SEK 0.9 -2.6 20.3 -6
US
Eli Lilly and Co
NYSE:LLY
676.4B USD 13.8 60.9 32.8 35.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.9B USD 4.1 16.9 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.6
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.1 17.1 10.1 13.5
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3.1 11.2 8.4 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.6B USD 2.1 16.8 7.3 10.2
P/E Multiple
Earnings Growth PEG
SE
Orexo AB
STO:ORX
Average P/E: 24.4
Negative Multiple: -2.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
60.9
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 395.6
20.3
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
32.8
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 1 866.6
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.5
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1